Zoetis Inc. (ETR:ZOE)

Germany flag Germany · Delayed Price · Currency is EUR
122.56
-1.90 (-1.53%)
Sep 17, 2025, 9:04 AM CET
-1.53%
Market Cap55.18B
Revenue (ttm)7.99B
Net Income (ttm)2.22B
Shares Outn/a
EPS (ttm)4.95
PE Ratio24.81
Forward PE22.56
Dividend1.75 (1.43%)
Ex-Dividend DateJul 18, 2025
Volume1
Average Volume121
Open122.56
Previous Close124.46
Day's Range122.56 - 122.56
52-Week Range122.56 - 179.58
Beta0.89
RSI29.49
Earnings DateNov 3, 2025

About Zoetis

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other ph... [Read more]

Sector Healthcare
Founded 1950
Employees 13,800
Stock Exchange Deutsche Börse Xetra
Ticker Symbol ZOE
Full Company Profile

Financial Performance

In 2024, Zoetis's revenue was $9.26 billion, an increase of 8.33% compared to the previous year's $8.54 billion. Earnings were $2.49 billion, an increase of 6.06%.

Financial numbers in USD Financial Statements

News

Zoetis (ZTS) Stock Declines While Market Improves: Some Information for Investors

In the closing of the recent trading day, Zoetis (ZTS) stood at $146.25, denoting a -1.32% move from the preceding trading day.

1 day ago - Nasdaq

January 2028 Options Now Available For Zoetis (ZTS)

Investors in Zoetis Inc (Symbol: ZTS) saw new options begin trading today, for the January 2028 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the tim...

2 days ago - Nasdaq

Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain

ZTS secures CVMP's positive opinion recommending the approval of Portela, a long-acting OA pain therapy for cats, with final decision expected in late 2025.

2 days ago - Nasdaq

Zoetis (ZTS) Awaits EU Approval for Innovative Cat Osteoarthritis Therapy

Zoetis (ZTS) Awaits EU Approval for Innovative Cat Osteoarthritis Therapy

5 days ago - GuruFocus

Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--If approved, Zoetis' Portela will be the first long-acting anti-NGF mAb therapy for cats and is designed to provide 3 months of OA pain relief...

5 days ago - Business Wire

Argus Research Reiterates Buy Rating for ZTS with Price Target Unchanged | ZTS Stock News

Argus Research Reiterates Buy Rating for ZTS with Price Target Unchanged | ZTS Stock News

8 days ago - GuruFocus

Top 50 High-Quality Dividend Stocks For September 2025

I track a universe of 50 high-quality dividend growth stocks to identify attractive investment opportunities based on valuation and future return potential. My custom valuation model highlights 23 sto...

11 days ago - Seeking Alpha

ZOE Released White Paper on European VPP and Energy Storage Development

SHANGHAI, Sept. 3, 2025 /PRNewswire/ -- ZOE Energy Storage, a leading BloombergNEF tier 1 provider of integrated ESS solutions, released the European Virtual Power Plant (VPP) and Energy Storage Devel...

14 days ago - Wallstreet:Online

Zoetis: A Solid Dividend Growth Investment For The Long Haul

Zoetis leads in animal health with strong growth, innovation, and safe, fast-growing dividends—now trading near fair value. Learn why ZTS stock is a buy.

16 days ago - Seeking Alpha

Zoetis to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the Morgan Stanley 23rd Annual Global Health...

21 days ago - Business Wire

Zoetis Announces Pricing of $1.85 Billion of Senior Notes

Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.850 billion of senior notes, consisting of $850.0 million aggregate principal amount of 4.150% senior notes due 2028 and $1.0 billi...

5 weeks ago - Wallstreet:Online

Zoetis Announces Pricing of $1.85 Billion of Senior Notes

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.850 billion of senior notes, consisting of $850.0 million aggregate princ...

5 weeks ago - Business Wire

If You'd Invested $1,000 in Zoetis (ZTS) Stock 10 Years Ago, Here's How Much You'd Have Today

The short-term picture has been less rosy than the longer-term one.

5 weeks ago - The Motley Fool

ZOE's Dr Federica Amati: 'Taking the Tube is the unhealthiest part of my day — the pollutants are awful'

Waking up with water, a sauna at lunchtime and putting together a healthy meal are the doctor’s wellbeing secrets

5 weeks ago - Evening Standard

Top 50 High-Quality Dividend Stocks For August 2025

My investable universe of 50 high-quality dividend growth stocks aims to identify attractive opportunities based on valuation and future return potential. Currently, 20 stocks offer an estimated futur...

6 weeks ago - Seeking Alpha

Zoetis CEO: It's unclear if animal health will be a part of pharmaceutical tariffs

Kristin Peck, Zoetis CEO, joins 'Closing Bell: Overtime' to discuss Q2 earnings, tariff impact on business and domestic production.

6 weeks ago - CNBC Television

Zoetis CEO: It's unclear if animal health will be a part of pharmaceutical tariffs

Kristin Peck, Zoetis CEO, joins 'Closing Bell: Overtime' to discuss Q2 earnings, tariff impact on business and domestic production.

6 weeks ago - CNBC

Zoetis Lifts Outlook As Companion Animal Portfolio Offsets Librela Decline

Animal health firm Zoetis Inc.  ZTS on Tuesday reported a second-quarter 2025 adjusted earnings per share of $1.76, up from $1.56 a year ago, beating the consensus of $1.61.

6 weeks ago - Benzinga